{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:07:17Z","timestamp":1788325637132,"version":"build-2803163510"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Colorectal cancer is one of the most common causes of mortality worldwide. There are several potential risk factors responsible for the initiation and progression of colorectal cancer, including age, family history, a history of inflammatory bowel disease, and lifestyle factors such as physical activity and diet. For decades, there has been a vast amount of study on treatment approaches for colorectal cancer, which has led to conventional therapies such as chemotherapy, surgery, etc. Considering the high prevalence and incidence rate, scholars believe there is an urgent need for an alternative, more efficacious treatment with fewer adverse effects than the abovementioned treatments. Immunotherapy has emerged as a potential treatment alternative in a few years and has become one of the fastest-evolving therapeutic methods. Immunotherapy works by activating or enhancing the immune system\u2019s power to identify and attack cancerous cells. This review summarizes the most crucial new immunotherapy methods under investigation for colorectal cancer treatment, including Immune checkpoint inhibitors, CAR-T cell therapy, BiTEs, Tumor-infiltrating lymphocytes, and Oncolytic virus therapy. Furthermore, this study discusses the application of combination therapy, precision medicine, biomarker discovery, overcoming resistance, and immune-related adverse effects.<\/jats:p>","DOI":"10.1186\/s12964-023-01430-8","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T08:02:17Z","timestamp":1705651337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses"],"prefix":"10.1186","volume":"22","author":[{"given":"Amin","family":"Kamrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hassanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Ahmadian Heris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mohammadinasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Sadeghvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Valedkarimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Shomali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"1430_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669\u201385.","journal-title":"JAMA"},{"key":"1430_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2208375","volume":"387","author":"M Bretthauer","year":"2022","unstructured":"Bretthauer M, L\u00f8berg M, Wieszczy P, Kalager M, Emilsson L, Garborg K, Rupinski M, Dekker E, Spaander M, Bugajski M. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022;387:1547\u201356.","journal-title":"N Engl J Med"},{"key":"1430_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMra2200869","volume":"386","author":"FA Sinicrope","year":"2022","unstructured":"Sinicrope FA. Increasing incidence of early-onset colorectal cancer. N Engl J Med. 2022;386:1547\u201358.","journal-title":"N Engl J Med"},{"key":"1430_CR4","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3390\/ijms20092340","volume":"20","author":"M Elbadawy","year":"2019","unstructured":"Elbadawy M, Usui T, Yamawaki H, Sasaki K. Emerging roles of C-Myc in cancer stem cell-related signaling and resistance to cancer chemotherapy: a potential therapeutic target against colorectal cancer. Int J Mol Sci. 2019;20:2340.","journal-title":"Int J Mol Sci"},{"key":"1430_CR5","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3389\/fimmu.2020.01624","volume":"11","author":"NA Johdi","year":"2020","unstructured":"Johdi NA, Sukor NF. Colorectal cancer immunotherapy: options and strategies. Front Immunol. 2020;11:1624.","journal-title":"Front Immunol"},{"key":"1430_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"1430_CR7","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.3390\/cancers14174160","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, Wu X, Chen Y, Li M, Chen M. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022;14:4160.","journal-title":"Cancers"},{"key":"1430_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","volume":"17","author":"A Lemos de Matos","year":"2020","unstructured":"Lemos de Matos A, Franco LS, McFadden G. Oncolytic Viruses and the Immune System: The Dynamic Duo. Mol Ther Methods Clin Dev. 2020;17:349\u201358.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1430_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1634\/theoncologist.2019-0611","volume":"25","author":"F Loupakis","year":"2020","unstructured":"Loupakis F, Depetris I, Biason P, Intini R, Prete AA, Leone F, Lombardi P, Filippi R, Spallanzani A, Cascinu S. Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes. Oncologist. 2020;25:481\u20137.","journal-title":"Oncologist"},{"key":"1430_CR10","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3390\/cancers11101554","volume":"11","author":"Z Macek Jilkova","year":"2019","unstructured":"Macek Jilkova Z, Aspord C, Decaens T. Predictive factors for response to PD-1\/PD-L1 checkpoint inhibition in the field of hepatocellular carcinoma: current status and challenges. Cancers. 2019;11:1554.","journal-title":"Cancers"},{"key":"1430_CR11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1080\/21645515.2020.1782692","volume":"17","author":"T Yang","year":"2021","unstructured":"Yang T, Kong Z, Ma W. PD-1\/PD-L1 immune checkpoint inhibitors in glioblastoma: Clinical studies, challenges and potential. Hum Vaccin Immunother. 2021;17:546\u201353.","journal-title":"Hum Vaccin Immunother"},{"key":"1430_CR12","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2147\/IJGM.S408349","volume":"16","author":"J Li","year":"2023","unstructured":"Li J, Xu X. Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview. Int J Gen Med. 2023;16:1527\u201340.","journal-title":"Int J Gen Med"},{"key":"1430_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","volume":"128","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer. 2020;128:17\u201326.","journal-title":"Eur J Cancer"},{"key":"1430_CR14","doi-asserted-by":"crossref","unstructured":"Cohen R, Bennouna J, Meurisse A, Tournigand C, de La Fouchardi\u00e8re C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol M-L: RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. Journal for Immunotherapy of Cancer 2020, 8.","DOI":"10.1136\/jitc-2020-001499"},{"key":"1430_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, Geva R, J\u00e4ger D, Hara H, Burge M, O\u2019Neil B, Kavan P, Yoshino T, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11\u20139.","journal-title":"J Clin Oncol"},{"key":"1430_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659\u201370.","journal-title":"Lancet Oncol"},{"key":"1430_CR17","doi-asserted-by":"publisher","first-page":"iii93","DOI":"10.1093\/annonc\/mdu050","volume":"25","author":"R Stupp","year":"2014","unstructured":"Stupp R, Brada M, Van Den Bent M, Tonn JC. Pentheroudakis G: High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii93\u2013101.","journal-title":"Ann Oncol"},{"key":"1430_CR18","doi-asserted-by":"publisher","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, Bielack S, Abecassis N, Aro H, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee J. Bone sarcomas: ESMO\u2013PaedCan\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Anna Oncol. 2018;29:iv79\u201395.","journal-title":"Anna Oncol"},{"issue":"6081\u20136100","key":"1430_CR19","first-page":"e6026","volume":"184","author":"CR Good","year":"2021","unstructured":"Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell. 2021;184(6081\u20136100):e6026.","journal-title":"Cell"},{"key":"1430_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-el-Enein M. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19:342\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"1430_CR21","doi-asserted-by":"publisher","first-page":"841425","DOI":"10.3389\/fimmu.2022.841425","volume":"13","author":"S Qian","year":"2022","unstructured":"Qian S, Villarejo-Campos P, Guijo I, Hern\u00e1ndez-Villafranca S, Garc\u00eda-Olmo D, Gonz\u00e1lez-Soares S, Guadalajara H, Jim\u00e9nez-Galanes S, Qian C. Update for advance CAR-T therapy in solid tumors, clinical application in peritoneal carcinomatosis from colorectal cancer and future prospects. Front Immunol. 2022;13:841425.","journal-title":"Front Immunol"},{"key":"1430_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/vaccines7040149","volume":"7","author":"R Saleh","year":"2019","unstructured":"Saleh R, Toor SM, Khalaf S, Elkord E. Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4+ T cells. Vaccines. 2019;7:149.","journal-title":"Vaccines"},{"key":"1430_CR23","doi-asserted-by":"publisher","first-page":"e004400","DOI":"10.1136\/jitc-2021-004400","volume":"10","author":"Y Yamaguchi","year":"2022","unstructured":"Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, Jonsson VD, Zarif JC, Lee PP, Wang X. PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages. J Immunother Cancer. 2022;10:e004400.","journal-title":"J Immunother Cancer"},{"key":"1430_CR24","doi-asserted-by":"crossref","unstructured":"Chen J, Zhu T, Jiang G, Zeng Q, Li Z, Huang X: Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in Colorectal cancer. 2023.","DOI":"10.21203\/rs.3.rs-2557966\/v1"},{"key":"1430_CR25","doi-asserted-by":"publisher","first-page":"E6912","DOI":"10.1073\/pnas.1704008114","volume":"114","author":"G Enyindah-Asonye","year":"2017","unstructured":"Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H. CD318 is a ligand for CD6. Proc Natl Acad Sci. 2017;114:E6912\u201321.","journal-title":"Proc Natl Acad Sci"},{"key":"1430_CR26","first-page":"231","volume":"7","author":"UH Weidle","year":"2010","unstructured":"Weidle UH, Eggle D, Klostermann S, Swart GW. ALCAM\/CD166: cancer-related issues. Cancer Genomics Proteomics. 2010;7:231\u201343.","journal-title":"Cancer Genomics Proteomics"},{"key":"1430_CR27","doi-asserted-by":"publisher","first-page":"101575","DOI":"10.1016\/j.tranon.2022.101575","volume":"27","author":"S He","year":"2023","unstructured":"He S, Li S, Guo J, Zeng X, Liang D, Zhu Y, Li Y, Yang D, Zhao X. CD166-specific CAR-T cells potently target colorectal cancer cells. Transl Oncol. 2023;27:101575.","journal-title":"Transl Oncol"},{"key":"1430_CR28","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu CE, Sj\u00f6str\u00f6m M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res. 2021;27:5123\u201330.","journal-title":"Clin Cancer Res"},{"key":"1430_CR29","doi-asserted-by":"publisher","first-page":"958082","DOI":"10.3389\/fimmu.2022.958082","volume":"13","author":"F Li","year":"2022","unstructured":"Li F, Zhao S, Wei C, Hu Y, Xu T, Xin X, Zhu T, Shang L, Ke S, Zhou J, et al. Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors. Front Immunol. 2022;13:958082.","journal-title":"Front Immunol"},{"key":"1430_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000217555","volume":"9","author":"M Nap","year":"1988","unstructured":"Nap M, Mollgard K, Burtin P, Fleuren GJ. Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumor Biology. 1988;9:145\u201353.","journal-title":"Tumor Biology"},{"key":"1430_CR31","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers. Mol Ther. 2017;25:1248\u201358.","journal-title":"Mol Ther"},{"key":"1430_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/17512433.2017.1292124","volume":"10","author":"AA Aka","year":"2017","unstructured":"Aka AA, Rappaport JA, Pattison AM, Sato T, Snook AE, Waldman SA. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. Expert Rev Clin Pharmacol. 2017;10:549\u201357.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1430_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1158\/2326-6066.CIR-16-0362","volume":"6","author":"MS Magee","year":"2018","unstructured":"Magee MS, Abraham TS, Baybutt TR, Flickinger JC Jr, Ridge NA, Marszalowicz GP, Prajapati P, Hersperger AR, Waldman SA, Snook AE. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res. 2018;6:509\u201316.","journal-title":"Cancer Immunol Res"},{"key":"1430_CR34","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1172\/JCI131133","volume":"130","author":"A Alajati","year":"2020","unstructured":"Alajati A, D\u2019Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat J-P, Guccini I. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. J Clin Investig. 2020;130:2435\u201350.","journal-title":"J Clin Investig"},{"key":"1430_CR35","doi-asserted-by":"crossref","unstructured":"Li M, Li S, Zhao R, Lv J, Zheng D, Qin L, Li S, Wu Q, Long Y, Tang Z, et al: CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer. Clin Exp Med 2022.","DOI":"10.1007\/s10238-022-00967-1"},{"key":"1430_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00062752-200301000-00004","volume":"10","author":"S Hakomori","year":"2003","unstructured":"Hakomori S. Structure, organization, and function of glycosphingolipids in membrane. Curr Opin Hematol. 2003;10:16\u201324.","journal-title":"Curr Opin Hematol"},{"key":"1430_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-916","volume":"14","author":"L Stimmer","year":"2014","unstructured":"Stimmer L, Dehay S, Nemati F, Massonnet G, Richon S, Decaudin D, Klijanienko J, Johannes L. Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds. BMC Cancer. 2014;14:1\u201311.","journal-title":"BMC Cancer"},{"key":"1430_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00018-022-04524-7","volume":"79","author":"AV Mel\u00e9ndez","year":"2022","unstructured":"Mel\u00e9ndez AV, Velasco C\u00e1rdenas RM, Lagies S, Strietz J, Siukstaite L, Thomas OS, Tomisch J, Weber W, Kammerer B, R\u00f6mer W, Minguet S. Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells. Cell Mol Life Sci. 2022;79:513.","journal-title":"Cell Mol Life Sci"},{"key":"1430_CR39","doi-asserted-by":"publisher","first-page":"12605","DOI":"10.1073\/pnas.1000976107","volume":"107","author":"R Lutterbuese","year":"2010","unstructured":"Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS-and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci. 2010;107:12605\u201310.","journal-title":"Proc Natl Acad Sci"},{"key":"1430_CR40","doi-asserted-by":"crossref","unstructured":"Golubovskaya V, Sienkiewicz J, Sun J, Huang Y, Hu L, Zhou H, Harto H, Xu S, Berahovich R, Bodmer W, Wu L: mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth. Cancers (Basel) 2023, 15.","DOI":"10.3390\/cancers15102860"},{"key":"1430_CR41","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1158\/1078-0432.CCR-18-0786","volume":"24","author":"SJH Waaijer","year":"2018","unstructured":"Waaijer SJH, Warnders FJ, Stienen S, Friedrich M, Sternjak A, Cheung HK, van Scheltinga A, Schr\u00f6der CP, de Vries EGE, Lub-de Hooge MN. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager (89)Zr-AMG211 Targeting CEA-Positive Tumors. Clin Cancer Res. 2018;24:4988\u201396.","journal-title":"Clin Cancer Res"},{"key":"1430_CR42","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1158\/0008-5472.CAN-20-2219","volume":"81","author":"SS Kharkwal","year":"2021","unstructured":"Kharkwal SS, Johndrow CT, Veerapen N, Kharkwal H, Saavedra-Avila NA, Carre\u00f1o LJ, Rothberg S, Zhang J, Garforth SJ, Jervis PJ, et al. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Cancer Res. 2021;81:1788\u2013801.","journal-title":"Cancer Res"},{"key":"1430_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1358\/dof.2008.033.02.1172578","volume":"33","author":"PA Baeuerle","year":"2008","unstructured":"Baeuerle PA, Reinhardt C, Kufer P. BiTE: a new class of antibodies that recruit T-cells. Drugs Future. 2008;33:1\u201311.","journal-title":"Drugs Future"},{"key":"1430_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/CAD.0b013e3282f23287","volume":"19","author":"F Rivera","year":"2008","unstructured":"Rivera F, Vega-Villegas ME, L\u00f3pez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs. 2008;19:99\u2013113.","journal-title":"Anticancer Drugs"},{"key":"1430_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4161\/cam.18953","volume":"6","author":"S Imrich","year":"2012","unstructured":"Imrich S, Hachmeister M, Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr. 2012;6:30\u20138.","journal-title":"Cell Adh Migr"},{"key":"1430_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.bjc.6605364","volume":"102","author":"T Osada","year":"2010","unstructured":"Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, Lyerly HK, Morse MA. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA\/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer. 2010;102:124\u201333.","journal-title":"Br J Cancer"},{"key":"1430_CR47","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-015-1671-y","volume":"64","author":"T Osada","year":"2015","unstructured":"Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK. CEA\/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother. 2015;64:677\u201388.","journal-title":"Cancer Immunol Immunother"},{"key":"1430_CR48","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nri3328","volume":"12","author":"J Rossjohn","year":"2012","unstructured":"Rossjohn J, Pellicci DG, Patel O, Gapin L, Godfrey DI. Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol. 2012;12:845\u201357.","journal-title":"Nat Rev Immunol"},{"key":"1430_CR49","doi-asserted-by":"crossref","unstructured":"Presti D, Dall\u2019Olio FG, Besse B, Ribeiro JM, Di Meglio A, Soldato D: Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: a systematic review. Critical Reviews in Oncology\/Hematology 2022:103773.","DOI":"10.1016\/j.critrevonc.2022.103773"},{"key":"1430_CR50","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/1538-7445.SABCS19-PD5-03","volume":"80","author":"S Loi","year":"2020","unstructured":"Loi S, Winer E, Lipatov O, Goncalves A. Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). Can Res. 2020;80:1158\u20139.","journal-title":"Can Res"},{"key":"1430_CR51","first-page":"e31144","volume":"14","author":"M Vitorino","year":"2022","unstructured":"Vitorino M, Eiriz I, Tom\u00e1s TC, Vicente R, Mendes A, Freitas AR, Alves-Vale C, Ferreira A. Leal da Costa L, Braga S, Borralho P: Association of Tumor-Infiltrating Lymphocytes With Survival in Stages II and III Colorectal Cancer. Cureus. 2022;14:e31144.","journal-title":"Cureus"},{"key":"1430_CR52","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2020.00683","volume":"11","author":"T Shi","year":"2020","unstructured":"Shi T, Song X, Wang Y, Liu F, Wei J. Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment. Front Immunol. 2020;11:683.","journal-title":"Front Immunol"},{"key":"1430_CR53","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/psp4.12898","volume":"12","author":"M Ahamadi","year":"2023","unstructured":"Ahamadi M, Kast J, Chen PW, Huang X, Dutta S, Upreti VV. Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. CPT Pharmacometrics Syst Pharmacol. 2023;12:250\u201360.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1430_CR54","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"1430_CR55","doi-asserted-by":"publisher","first-page":"1029269","DOI":"10.3389\/fimmu.2022.1029269","volume":"13","author":"MJF Crupi","year":"2022","unstructured":"Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, et al. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer. Front Immunol. 2022;13:1029269.","journal-title":"Front Immunol"},{"key":"1430_CR56","doi-asserted-by":"crossref","unstructured":"Chai C, Zhang J, Zhou Y, Yin H, Zhang F, Diao Y, Zan X, Ma Y, Wang Y, Wu Y, Wang W: The Effects of Oncolytic Pseudorabies Virus Vaccine Strain Inhibited the Growth of Colorectal Cancer HCT-8 Cells In Vitro and In Vivo. Animals (Basel) 2022, 12.","DOI":"10.3390\/ani12182416"},{"key":"1430_CR57","doi-asserted-by":"crossref","unstructured":"Monge C, Xie C, Myojin Y, Coffman K, Hrones DM, Wang S, Hernandez JM, Wood BJ, Levy EB, Juburi I, et al: Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. J Immunother Cancer 2023, 11.","DOI":"10.1136\/jitc-2022-005640"},{"key":"1430_CR58","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1002\/cam4.4845","volume":"11","author":"L Huang","year":"2022","unstructured":"Huang L, Zhao H, Shan M, Chen H, Xu B, He Y, Zhao Y, Liu Z, Chen J, Xu Q. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer. Cancer Med. 2022;11:4575\u201387.","journal-title":"Cancer Med"},{"key":"1430_CR59","doi-asserted-by":"publisher","first-page":"1159802","DOI":"10.3389\/fonc.2023.1159802","volume":"13","author":"J Zhang","year":"2023","unstructured":"Zhang J, He Q, Mao D, Wang C, Huang L, Wang M, Zhang J. Efficacy and adverse reaction management of oncolytic viral intervention combined with chemotherapy in patients with liver metastasis of gastrointestinal malignancy. Front Oncol. 2023;13:1159802.","journal-title":"Front Oncol"},{"key":"1430_CR60","doi-asserted-by":"crossref","unstructured":"Grenier SF, Khan MW, Reil KA, Sawaged S, Tsuji S, Giacalone MJ, Tian M, McGuire KL: VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC. Int J Mol Sci 2023, 24.","DOI":"10.3390\/ijms24129993"},{"key":"1430_CR61","doi-asserted-by":"publisher","first-page":"198979","DOI":"10.1016\/j.virusres.2022.198979","volume":"323","author":"N Zhang","year":"2022","unstructured":"Zhang N, Li J, Yu J, Wan Y, Zhang C, Zhang H, Cao Y. Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR\/Cas9 system for colon cancer treatment. Virus Res. 2022;323:198979.","journal-title":"Virus Res"},{"key":"1430_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz H-J. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2013a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"key":"1430_CR63","doi-asserted-by":"publisher","first-page":"2118210","DOI":"10.1080\/2162402X.2022.2118210","volume":"11","author":"X Li","year":"2022","unstructured":"Li X, Lu M, Yuan M, Ye J, Zhang W, Xu L, Wu X, Hui B, Yang Y, Wei B, et al. CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy. Oncoimmunology. 2022;11:2118210.","journal-title":"Oncoimmunology"},{"key":"1430_CR64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.antiviral.2016.03.002","volume":"130","author":"W Tong","year":"2016","unstructured":"Tong W, Li G, Liang C, Liu F, Tian Q, Cao Y, Li L, Zheng X, Zheng H, Tong G. A live, attenuated pseudorabies virus strain JS-2012 deleted for gE\/gI protects against both classical and emerging strains. Antiviral Res. 2016;130:110\u20137.","journal-title":"Antiviral Res"},{"key":"1430_CR65","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13045-022-01370-9","volume":"15","author":"M Toulmonde","year":"2022","unstructured":"Toulmonde M, Cousin S, Kind M, Guegan JP, Bessede A, Le Loarer F, Perret R, Cantarel C, Bellera C, Italiano A. Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma. J Hematol Oncol. 2022;15:149.","journal-title":"J Hematol Oncol"},{"key":"1430_CR66","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1126\/science.abk3436","volume":"374","author":"A Melcher","year":"2021","unstructured":"Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science. 2021;374:1325\u20136.","journal-title":"Science"},{"key":"1430_CR67","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"1430_CR68","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","volume":"18","author":"K Twumasi-Boateng","year":"2018","unstructured":"Twumasi-Boateng K, Pettigrew JL, Kwok YE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. 2018;18:419\u201332.","journal-title":"Nat Rev Cancer"},{"key":"1430_CR69","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.21873\/anticanres.11218","volume":"36","author":"BM Hancock","year":"2016","unstructured":"Hancock BM, McGuire KL, Tsuji S, Reil K, Hernandez V, Giacalone MJ, Godbey W. A single intravesical instillation of VAX014 inhibits orthotopic superficial bladder tumor implantation to increase survival. Anticancer Res. 2016;36:6243\u20138.","journal-title":"Anticancer Res"},{"key":"1430_CR70","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","volume":"357","author":"RJ Whitley","year":"2001","unstructured":"Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357:1513\u20138.","journal-title":"Lancet"},{"key":"1430_CR71","doi-asserted-by":"publisher","unstructured":"Pan S, Liu X, Ma Y, Cao Y, He B: Herpes simplex virus 1 \u03b3134. 5 protein inhibits STING activation that restricts viral replication. J Virol 2018, 92:https:\/\/doi.org\/10.1128\/jvi. 01015-01018.","DOI":"10.1128\/jvi"},{"key":"1430_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0218-5","volume":"5","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017;5:1\u201315.","journal-title":"J Immunother Cancer"},{"key":"1430_CR73","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ccell.2021.04.005","volume":"39","author":"O Klein","year":"2021","unstructured":"Klein O, Kee D, Markman B, Carlino MS, Underhill C, Palmer J, Power D, Cebon J, Behren A. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1\/CTLA-4 combination immunotherapy. Cancer Cell. 2021;39:592\u20133.","journal-title":"Cancer Cell"},{"key":"1430_CR74","doi-asserted-by":"publisher","first-page":"613","DOI":"10.21873\/anticanres.16197","volume":"43","author":"M Xu","year":"2023","unstructured":"Xu M, Tsunedomi R, Kiyotani K, Tomochika S, Furuya K, Nakajima M, Matsui H, Tokumitsu Y, Shindo Y, Yoshida S. Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal Cancer. Anticancer Res. 2023;43:613\u201320.","journal-title":"Anticancer Res"},{"key":"1430_CR75","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, Thel H, Hoyos D, Mehta A, Arshad S. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nature cancer. 2021;2:1124\u201335.","journal-title":"Nature cancer"},{"key":"1430_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0575-3","volume":"7","author":"R Gonzalez-Exposito","year":"2019","unstructured":"Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K, Challoner B, Patel R. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer. 2019;7:1\u201314.","journal-title":"J Immunother Cancer"},{"key":"1430_CR77","doi-asserted-by":"crossref","unstructured":"Lao Y, Shen D, Zhang W, He R, Jiang M: Immune Checkpoint Inhibitors in Cancer Therapy-How to Overcome Drug Resistance? Cancers (Basel) 2022, 14.","DOI":"10.3390\/cancers14153575"},{"key":"1430_CR78","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40259-020-00420-3","volume":"34","author":"DR Almquist","year":"2020","unstructured":"Almquist DR, Ahn DH, Bekaii-Saab TS. The role of immune checkpoint inhibitors in colorectal adenocarcinoma. BioDrugs. 2020;34:349\u201362.","journal-title":"BioDrugs"},{"key":"1430_CR79","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2020.10.040","volume":"498","author":"M Feng","year":"2021","unstructured":"Feng M, Zhao Z, Yang M, Ji J, Zhu D. T-cell-based immunotherapy in colorectal cancer. Cancer Lett. 2021;498:201\u20139.","journal-title":"Cancer Lett"},{"key":"1430_CR80","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-023-01430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-023-01430-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-023-01430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T12:04:56Z","timestamp":1705665896000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-023-01430-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1186\/s12964-023-01430-8","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}